What is the typical CJC-1295 No DAC dose?
Research-protocol CJC-1295 No DAC doses typically span 100-200 mcg per dose on a once-daily or twice-daily subcutaneous schedule. The short ~30-minute half-life supports pulsatile GH release at each dose; daily dosing pre-sleep fasted is the most common protocol pattern.
What the research literature says
The CJC-1295 No DAC dose framework is informed by the broader CJC-1295 development program — the Jetté identification work characterised the GHRH-receptor pharmacology (PMID 15817669), the Teichman clinical-pharmacology study in healthy adults characterised the dose-response framework anchored to the DAC variant (PMID 16352683), and the Alba GHRH-knockout mouse model confirmed receptor specificity (PMID 16822960).
The No DAC variant’s dose framework reflects the shorter half-life — daily dosing at 100-200 mcg produces a single GH pulse per dose without sustained accumulation. The combined CJC-1295 + Ipamorelin protocol pairs the GHRH-receptor engagement (from CJC-1295 No DAC) with ghrelin-receptor engagement (from ipamorelin) to produce additive GH release. Typical combined doses use 100-200 mcg of each component per dose, delivered together in a single syringe draw.
The Ionescu pulsatile-GH-secretion work documented that pulsatile GH release persists during continuous GHRH stimulation (PMID 17018654) — for the No DAC variant the dosing-interval framework is set by the short half-life rather than by sustained-stimulation considerations.
Why this matters in research context
The 100-200 mcg per dose tier is the operational anchor for most CJC-1295 No DAC research protocols. The pre-sleep fasted timing maximises alignment with the natural GH-secretion peak. Researchers using the combined CJC-1295 + Ipamorelin Blend format typically maintain the same per-component dose tier; the blend’s fixed-ratio loadings (5 mg + 5 mg per vial) support this directly without separate component-volume math.
Related compounds
- CJC-1295 No DAC 10mg — the compound covered by this answer
- CJC-1295 + Ipamorelin Blend — combined-formulation
Related research questions
- What is the half-life of CJC-1295 No DAC?
- How much bacteriostatic water with CJC-1295 No DAC?
- Can CJC-1295 be stacked with ipamorelin?
References
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-3058. [PMID 15817669]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
- Alba M et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab 2006;291(6):E1290-E1294. [PMID 16822960]
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-4797. [PMID 17018654]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. CJC-1295 No DAC is sold strictly as a research-grade reagent for laboratory and bench research applications.